NO743556L - - Google Patents
Info
- Publication number
- NO743556L NO743556L NO743556A NO743556A NO743556L NO 743556 L NO743556 L NO 743556L NO 743556 A NO743556 A NO 743556A NO 743556 A NO743556 A NO 743556A NO 743556 L NO743556 L NO 743556L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compounds
- acid
- benzo
- stands
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- KWWCXEXKKYYNRF-UHFFFAOYSA-N 4-methoxy-4-oxobutanoic acid;hydrochloride Chemical compound Cl.COC(=O)CCC(O)=O KWWCXEXKKYYNRF-UHFFFAOYSA-N 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 150000003577 thiophenes Chemical class 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002579 anti-swelling effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- -1 ester halides Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
- C07D333/80—Seven-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
"FrtBragangsmåte for £r«m»tilling ay nye» heterocykHske forbindelser". "Procedure for £r«m»tilling and new" heterocyclic compounds".
Foreliggende oppfinnelse vedrorer en fremgangsmåte for fremstilling av nye forbindelser med formel I The present invention relates to a method for the production of new compounds with formula I
hvori R^betyr hydrogen, fluor, klor, brom eller lavere alkyl, R2betyr hydrogen eller lavere alkyl, R^og R^står hver for hydrogen eller står sammen for oksygen, n betyr 2, 3 eller h og A står for en etylen- eller vinylen-gruppe, og salter av syrene med formel I. in which R^ means hydrogen, fluorine, chlorine, bromine or lower alkyl, R2 means hydrogen or lower alkyl, R^ and R^ each stand for hydrogen or together stand for oxygen, n means 2, 3 or h and A stands for an ethylene- or vinylene group, and salts of the acids of formula I.
Det særegne ved fremgangsmåten i henhold til oppfinnelsen er at enten The peculiarity of the method according to the invention is that either
a) forbindelser med formel IIa) compounds of formula II
hvori R.j , R^, R^og Å har den ovennevnte betydning, omsettes med in which R.j , R^, R^and Å have the above-mentioned meaning, are traded with
forbindelser med formel IIIcompounds of formula III
hvori n har den ovennevnte betydning og X står for klor eller brom og Y står for lavere alkyl og X og Y sammen danner en binding, eller in which n has the above meaning and X stands for chlorine or bromine and Y stands for lower alkyl and X and Y together form a bond, or
■ b) for fremstilling av forbindelser med formel Ia hvori , R^, R^, A og n har den ovennevnte betydning, hydrolyseres forbindelser med formel Ib ■ b) for the preparation of compounds of formula Ia in which , R^, R^, A and n have the above meaning, compounds of formula Ib are hydrolyzed
hvori R^, R^, R^, A og n har den ovennevnte betydning og R2^ står for lavere alkyl in which R^, R^, R^, A and n have the above meaning and R2^ stands for lower alkyl
og mulige forbindelser med formel Ia overfores eventuelt i sine salter. and possible compounds of formula Ia are optionally transferred in their salts.
I forbindelsene med formel I står R1foretrukket for hydrogen eller klor og er foretrukket anordnet i 6- eller 7-stilling av ring-skjelettet. Hvis R^betyr lavere alkyl, inneholder dette foretrukket 1 til h karbonatomer og utgjor spesielt metyl. Substituenten R£står foretrukket for hydrogen. Hvis Rg betyr lavere alkyl, inneholder dette f.eks. 1 til h karbonatomer og utgjor spesielt metyl-eller etylgruppen. Foretrukket står R^ og R^felles for oksygen og n står foretrukket for 2. In the compounds of formula I, R1 preferably stands for hydrogen or chlorine and is preferably arranged in the 6- or 7-position of the ring skeleton. If R₂ means lower alkyl, this preferably contains 1 to h carbon atoms and is especially methyl. The substituent R£ is preferably hydrogen. If Rg means lower alkyl, this contains e.g. 1 to h carbon atoms and make up especially the methyl or ethyl group. Preferably, R^ and R^ jointly stand for oxygen and n preferably stands for 2.
Omsetningen av forbindelsene med formel II med forbindelsene med formel III i henhold til fremgangsmåtevariant a) gjennomfores fore trukket i nærvær av et surt kondensasjonsmiddel. Ved en foretrukket' utforelsesform av fremgangsmåten kan omsetningen f.eks. skje i nærvær av en Lewis-syre i et under reaks j ons be ting el sene. inert organisk løsningsmiddel, f.eks. i et klorert hydrokarbon som metylenklorid eller karbontetraklorid eller i karbondisulfid, The reaction of the compounds of formula II with the compounds of formula III according to method variant a) is preferably carried out in the presence of an acidic condensation agent. In a preferred embodiment of the method, the turnover can e.g. happen in the presence of a Lewis acid in a sub-reaction condition. inert organic solvent, e.g. in a chlorinated hydrocarbon such as methylene chloride or carbon tetrachloride or in carbon disulfide,
under reaksjonsbetingelsene for en Friedel-Crafts-reaksjon. Somunder the reaction conditions of a Friedel-Crafts reaction. As
. Lewis-syre egner seg f.eks. aluminiumtriklorid eller tinntetraklorid. Omsetningen av forbindelsene med formel II med forbindelsene med formel III kan også gjennomfores i nærvær av sterke mineral-syrer som f.eks. polyfosforsyre eller fosforsyre, eventuelt under tilsetning av et under reaks jonsbetingelsene inert organisk løsningsmiddel, f.eks. et hydrokarbon som benzen, toluen, xylen eller tetralin. Hvis omsetningen skjer i nærvær av en Lewis-syre, kan reaksjonstemperaturen foretrukket ligge mellom romtemperaturen og koketemperaturen for reaksjonsblandingen og reaksjonstiden kan utgjore fra 5 minutter til 2h timer. Omsetningen i nærvær av en sterk mineralsyre gjennomfores foretrukket ved temperaturer mellom ca. 50 og l50°C og kan vare mellom 30 minutter og 2h timer. Ved omsetningen i nærvær av en sterk mineralsyre hydrolyseres mulige estergrupperinger - COOR^ samtidig slik at forbindelser med formel Ia erholdes. . Lewis acid is suitable, e.g. aluminum trichloride or tin tetrachloride. The reaction of the compounds of formula II with the compounds of formula III can also be carried out in the presence of strong mineral acids such as e.g. polyphosphoric acid or phosphoric acid, optionally with the addition of an organic solvent inert under the reaction conditions, e.g. a hydrocarbon such as benzene, toluene, xylene or tetralin. If the reaction takes place in the presence of a Lewis acid, the reaction temperature can preferably lie between room temperature and the boiling temperature of the reaction mixture and the reaction time can be from 5 minutes to 2 hours. The reaction in the presence of a strong mineral acid is preferably carried out at temperatures between approx. 50 and 150°C and can last between 30 minutes and 2 hours. During the reaction in the presence of a strong mineral acid, possible ester groupings - COOR^ are simultaneously hydrolysed so that compounds of formula Ia are obtained.
Hydrolysen av esterne med formel Ib i henhold til fremgangsmåtevariant b) kan gjennomfores etter i og for seg for esterspalting vanlige metoder. F.eks. kan forbindelsene med formel Ib hydrolyseres i nærvær av en base, f.eks. et alkalimetall- eller jordalkalimetall-hydroksyd, eller i nærvær av en sur katalysator, f.eks. en mineralsyre som saltsyre eller svovelsyre eller en organisk sulfonsyre. Hydrolysen kan skje ved temperaturer mellom romtemperatur og ca. 100°C eventuelt under tilsetning av et under reaksjonsbetingelsene inert med vann blandbart organisk løsningsmiddel. Foretrukket gjennomfores hydrolysen i alkalisk medium, f.eks. med minst en ekvivalent mengde av en vandig alkalimetallhydroksyd-losning ved romtemperatur eller svakt forhoyet temperatur. Som eventuelt til-satt organisk løsningsmiddel egner seg f.eks. lavere alkoholer, aceton eller cykliske etere som tetrahydrofuran eller dioksan. Forbindelsene med formel I kan isoleres fra reaksjonsblandingen og renses på i og for seg kjent måte. De fri syrer med formel Ia kan eventuelt overfores i sine salter og omvendt. The hydrolysis of the esters of formula Ib according to process variant b) can be carried out according to the usual methods for ester cleavage. E.g. the compounds of formula Ib can be hydrolysed in the presence of a base, e.g. an alkali metal or alkaline earth metal hydroxide, or in the presence of an acid catalyst, e.g. a mineral acid such as hydrochloric or sulfuric acid or an organic sulphonic acid. The hydrolysis can take place at temperatures between room temperature and approx. 100°C optionally with the addition of an organic solvent miscible with water that is inert under the reaction conditions. The hydrolysis is preferably carried out in an alkaline medium, e.g. with at least an equivalent amount of an aqueous alkali metal hydroxide solution at room temperature or slightly elevated temperature. As an optionally added organic solvent, e.g. lower alcohols, acetone or cyclic ethers such as tetrahydrofuran or dioxane. The compounds of formula I can be isolated from the reaction mixture and purified in a manner known per se. The free acids of formula Ia can optionally be transferred into their salts and vice versa.
Utgangsforbindelser med formel IlaOutput compounds of formula Ila
hvori R.| og A har den ovennevnte betydning, kan f.eks. fremstilles ved at forbindelser med formel Ilb in which R.| and A has the above meaning, can e.g. is produced by compounds of formula IIb
hvori IL og A har den ovennevnte betydning, reduseres. Reduksjonen kan f.eks. skje etter Clemmensen med amalgamert sink/saltsyre eller, hvis A står for en etylengruppe, også ved behandling med natrium/alkohol. in which IL and A have the above meaning, is reduced. The reduction can e.g. happen according to Clemmensen with amalgamated zinc/hydrochloric acid or, if A stands for an ethylene group, also by treatment with sodium/alcohol.
Forbindelsene med formel I og deres farmakologisk tålbare salter er tidligere ikke beskrevet i litteraturen. De utmerker seg ved interessante farmakodynamiske egenskaper og kan folgelig anvendes som medisin. De besitter antiflogistiske egenskaper som kan påvises ved dyreforsøk. Således hemmer de i rotter odemdannelse ved Carragen-poteodem-proven i doser på ca. 5 til 100 mg/kg kroppsvekt og i subkronisk granulom-pung-prove i doser på ca. 20 til 100 mg/kg kroppsvekt. The compounds of formula I and their pharmacologically tolerable salts have not previously been described in the literature. They are distinguished by interesting pharmacodynamic properties and can therefore be used as medicine. They possess antiphlogistic properties that can be demonstrated in animal experiments. Thus, in rats, they inhibit edema formation in the Carrageen-poteodem test in doses of approx. 5 to 100 mg/kg body weight and in subchronic granuloma-sac sample in doses of approx. 20 to 100 mg/kg body weight.
På grunn av disse virkninger kan substansene finne anvendelse som antiflogistika henhv. for hemming av eksudasjonen ved betennelser henhv. ved ødemer. De doser som anvendes varierer selvfølgelig alt etter arten av forbindelsen, tilførselsmåten og den tilstand som skal behandles. Vanlig oppnås dog tilfredsstillende resultater med en dose på 5 til 100 mg/kg kroppsvekt. Denne dose kan om nødvendig tilføres i 2 til h deldoser eller også som retardform. For større pattedyr ligger dagsdosen ved omtrent 100 til 1000 mg. For oral tilførsel kan deldosene f.eks. inneholde omtrent 25 til 500 mg av forbindelsene med formel I ved siden av faste eller flytende bærersubstanser. Due to these effects, the substances can be used as antiphlogistics or for inhibiting the exudation in inflammation or in case of edema. The doses used vary, of course, according to the nature of the compound, the method of administration and the condition to be treated. Usually, however, satisfactory results are achieved with a dose of 5 to 100 mg/kg body weight. If necessary, this dose can be given in 2 to 1 hour sub-doses or also as a slow-release form. For larger mammals, the daily dose is approximately 100 to 1000 mg. For oral administration, the partial doses can e.g. contain about 25 to 500 mg of the compounds of formula I in addition to solid or liquid carrier substances.
Forbindelsene med formel I besitter likeledes en arthritis-hemmende virkning. Således virker de f.eks. ved Freund-Adjuvans-arthritis-latenstidforsøk i rotter svellingshemmende i doser på -ca. 30 til 100 mg/kg kroppsvekt. The compounds of formula I likewise possess an arthritis-inhibiting effect. Thus they work, e.g. in Freund-Adjuvant-arthritis-latency-time experiments in rats anti-swelling in doses of -approx. 30 to 100 mg/kg body weight.
På grunn av deres arthritis-hemmende virkning kan forbindelsene anvendes for- profylakse og behandling av arthritis og reumatiske sykdommer. De anvendte doser varierer selvfølgelig alt etter arten av forbindelsen, tilførselsmåten og den tilstand som skal behandles. Vanlig oppnås dog tilfredsstillende resultater med en dose på 30 til 100 mg/kg kroppsvekt. Denne dose kan om nødvendig tilfores i 2 til h deldoser eller også som retardform. For større pattedyr ligger dagsdosen ved omtrent 100 til 1000 mg. For oral tilførsel kan deldosene f.eks. inneholde omtrent 25 til 500 mg av forbindelsene med formel I ved siden av faste eller flytende bærersubstanser. Som Due to their arthritis-inhibiting effect, the compounds can be used for the prophylaxis and treatment of arthritis and rheumatic diseases. The doses used vary, of course, according to the nature of the compound, the method of administration and the condition to be treated. However, satisfactory results are usually achieved with a dose of 30 to 100 mg/kg body weight. If necessary, this dose can be administered in 2 to 1 hour partial doses or also as a slow-release form. For larger mammals, the daily dose is approximately 100 to 1000 mg. For oral administration, the partial doses can e.g. contain about 25 to 500 mg of the compounds of formula I in addition to solid or liquid carrier substances. As
særlig egnet har forbindelsen h- (9,10-dihydro-1+-okso-ifH-benzo/J+,57 cyklohepta/i ,2-b/tiofen-2-yl)-^-oksosmørsyre og dens salter vist particularly suitable, the compound h-(9,10-dihydro-1+-oxo-ifH-benzo[J+,57 cyclohepta[i,2-b]thiophen-2-yl)-^-oxobutyric acid and its salts have been shown
seg. themselves.
Som legemiddel kan de nye forbindelser henhv. deres fysiologisk tålbare salter tilføres alene eller i passende preparatform med farmakologisk indifferente hjelpestoffer. As medicine, the new compounds can resp. their physiologically tolerable salts are added alone or in suitable preparation form with pharmacologically indifferent excipients.
I den utstrekning fremstillingen av utgangsforbindelsene ikke er To the extent that the production of the output compounds is not
beskrevet er disse kjente eller kan fremstilles etter i og for seg kjente metoder henhv. analogt med de her beskrevne eller analogt described, these are known or can be produced according to per se known methods or analogous to those described here or analogously
i in
med i og for seg kjente metoder.with per se known methods.
I de etterfølgende eksempler, som skal illustrere oppfinnelsen,In the following examples, which shall illustrate the invention,
er alle temperaturangivelser i °C.are all temperature indications in °C.
Eksempel 1 ; |+-(gjIQ^di^dro^H-te^ Example 1; |+-(gjIQ^di^dro^H-te^
tiofen =2-y_l)-^ =oksosmorsy_rethiophene =2-y_l)-^ =oxosomer_re
11,0 g ravsyreanhydrid loses i 220 ml vannfri metylenklorid under oppvarming, den erholdte løsning avkjøles til 20°C og tilsettes pørsjonsvis 30 g aluminiumklorid. Etter 15 minutters omrøring ved romtemperatur tildryppes i løpet av 30 minutter en løsning av 22,0 g 9 jlO-dihydro-i+H-benzo</>^j^/c<y>klohe<p>ta/l,2-b7tiof en i 100 ml vannfri 11.0 g of succinic anhydride is dissolved in 220 ml of anhydrous methylene chloride while heating, the resulting solution is cooled to 20°C and 30 g of aluminum chloride is added in portions. After stirring for 15 minutes at room temperature, a solution of 22.0 g of 9 jlO-dihydro-i+H-benzo</>^j^/c<y>klohe<p>ta/l,2- is added dropwise over the course of 30 minutes b7tiof one in 100 ml anhydrous
metylenklorid, den erholdte bla'nding omrøres videre i h5 minutter ved romtemperatur og uthelles på en blanding av 200 ml konsentrert saltsyre og 200 g is. Etter tilsetning av 300 ml metylenklorid oppvarmes hele blandingen i 15 minutter på vannbad, avkjøles, metylenkloridet fraskilles og den vandige fase ekstraheres videre med metylenklorid. Fra de forenede metylenkloridløsninger methylene chloride, the resulting mixture is further stirred for 5 minutes at room temperature and poured onto a mixture of 200 ml of concentrated hydrochloric acid and 200 g of ice. After adding 300 ml of methylene chloride, the entire mixture is heated for 15 minutes in a water bath, cooled, the methylene chloride is separated and the aqueous phase is further extracted with methylene chloride. From the combined methylene chloride solutions
ekstraheres den sure andel med 0,5 I natronlut, det basiske uttrekk syres med 5 N saltsyre og utrystes med kloroform. Kloroformløsning-ene vaskes med vann, tørres over magnesiumsulfat, filtreres gjennom aktivkull og inndampes til tørrhet. Den som fast rest tilbake-blivende i. overskriften nevnte forbindelse omkrystalliseres fra dimetylformamid/aceton. Smeltepunkt: 202 - 203°C. the acidic part is extracted with 0.5 I caustic soda, the basic extract is acidified with 5 N hydrochloric acid and shaken off with chloroform. The chloroform solutions are washed with water, dried over magnesium sulphate, filtered through activated charcoal and evaporated to dryness. The compound mentioned in the title remaining as a solid residue is recrystallized from dimethylformamide/acetone. Melting point: 202 - 203°C.
Utgangsmaterialet kan erholdes på følgende måte:The starting material can be obtained in the following way:
Til løsningen av 25,0 g 9510-dihydro^VH-benzo/I+,57cykloh.epta/1 ,2-b7 tiofen-^-on. i 280 ml vannfri etanol tilsettes porsjonsvis 25,0 g natrium. Etter at alt er oppløst oppvarmes reaksjonsblandingen i 2-|- time til koking og løsningsmidlet avdampes under redusert trykk. Inndampningsresten tilsettes langsomt 500 ml isblandet vann og tilsettes 200 ml metylenklorid, den organiske fase fraskilles og den vandige løsning ekstraheres på nytt med metylenklorid. De forenede organiske løsninger vaskes nøytrale med vann, tørres over natriumsulfat og inndampes. Resten krystalliseres fra etanol. To the solution of 25.0 g of 9510-dihydro^VH-benzo/I+,57cyclohepta/1,2-b7thiophen-^-one. 25.0 g of sodium are added in portions to 280 ml of anhydrous ethanol. After everything has dissolved, the reaction mixture is heated to boiling for 2 hours and the solvent is evaporated under reduced pressure. The evaporation residue is slowly added to 500 ml of ice-mixed water and 200 ml of methylene chloride is added, the organic phase is separated and the aqueous solution is extracted again with methylene chloride. The combined organic solutions are washed neutral with water, dried over sodium sulphate and evaporated. The residue is crystallized from ethanol.
Smeltepunktet for 9, 10-dihydro-^H-benzo/<!>+,57cyklohepta/l ,2-b<7>tiofen:- 117- 119°C The melting point of 9, 10-dihydro-^H-benzo[!>+,57cyclohepta/l ,2-b<7>thiophene:- 117-119°C
Eksempel<2>t !+ii9ilO-dihydro-^=okso=^H=benzo Example<2>t !+ii9ilO-dihydro-^=oxo=^H=benzo
ii2£25i?-<y>^)-^-ok^osmor^y^eii2£25i?-<y>^)-^-ok^osmor^y^e
Etter den i eksempel 1 beskrevne fremgangsmåte erholdes fra 12,2 g ravsyreanhydrid, 30 g aluminiumklorld og 1550 g 9 ? 1O-dihydro-J+H-benzo/T+,5/cyklohepta/i ,2-b/tiofen-^-on i 320 ml vannfri metylenklorid den i overskriften nevnte forbindelse med smeltepunkt 167 - 168°C (fra etanol/eter). According to the method described in example 1, 12.2 g of succinic anhydride, 30 g of aluminum chloride and 1550 g of 9 ? 1O-dihydro-J+H-benzo/T+,5/cyclohepta/i ,2-b/thiophen-^-one in 320 ml of anhydrous methylene chloride the compound mentioned in the title with melting point 167 - 168°C (from ethanol/ether) .
Eksempel 3; ?i (|+ioks.o-^H-benzo^^^cyklohe Example 3; ?i (|+ioks.o-^H-benzo^^^cyclohe
5i2ksoyaleriansyre5i2xoyaleric acid
Etter den i eksempel 1 beskrevne fremgangsmåte erholdes fra 13 ?0 g glutarsyreanhydrid 30 g aluminiumklorid og 15,0 g ^H-benzo/^f,57 cyklohepta/l , 2-b/t i of en-^--on i 350 ml vannfri metylenklorid den i overskriften nevnte forbindelse med smeltepunkt lh9 - 1 51 °C (omkrystallisert to ganger fra aceton). According to the method described in example 1, 30 g of aluminum chloride and 15.0 g of ^H-benzo/^f,57 cyclohepta/l , 2-b/t i of en-^--one are obtained from 13 ?0 g of glutaric anhydride in 350 ml anhydrous methylene chloride the compound mentioned in the title with melting point lh9 - 1 51 °C (recrystallized twice from acetone).
Analogt med eksempel 1 kan også de .følgende (I+H-benzo-/!+, 5/cyklohepta/1 ,2-b/tiofen-2-yl)-oksokarboksylsyrederivater erholdes ved omsetning av tilsvarende 1+H-benzo-/rF,57cyklohepta/l ,2-b/tiofen-derivater med tilsvarende dikarboksylsyreanhydrider: Analogous to example 1, the following (I+H-benzo-/!+,5/cyclohepta/1,2-b/thiophen-2-yl)-oxocarboxylic acid derivatives can also be obtained by reacting the corresponding 1+H-benzo-/ rF,57cyclohepta/l,2-b/thiophene derivatives with corresponding dicarboxylic acid anhydrides:
Eksempel 1 5: . h- (9^1 ^~ §:V^ y^ 2zh:z2^ 2z^ z^^ 2^ 1^ 21^ 2^^^-/i^2-b/tiofen-2-yl)-^-oksosmorsyremetylester Example 1 5: . h- (9^1 ^~ §:V^ y^ 2zh:z2^ 2z^ z^^ 2^ 1^ 21^ 2^^^-/i^2-b/thiophen-2-yl)-^- oxosuccinic acid methyl ester
Til en suspensjon av10,0 g 9 510-dihydro-^-H^benzo-/^:,<57cyklohepta/I ,2-b/tiof en-1!--on og 30,0 g vannfritt aluminiumklorid i 200 ml vannfritt karbondisulfid tildryppes en losning av 6,3 ml ravsyremonometylesterklorid i 100 ml vannfritt karbondisulfid ved 0°C, reaksjonsblandingen omrores videre i 6 timer ved romtemperatur, tilsettes ved 20 til 25°C dråpevis 23,3 g tinntetraklorid og omrores videre i 15 timer ved romtemperatur. Reaksjonsblandingen oppvarmes deretter i 2 timer ved 50°C, avkjoles, uthelles på 500 ml 5 N saltsyre og ekstraheres med kloroform. De organiske faser vaskes med 5 N saltsyre og med vann, torres over magnesiumsulfat og inndampes. Inndampningsresten loses i 300 ml metylenklorid, filtreres gjennom kiselgel og inndampes til torrhet. Den i overskriften nevnte forbindelse krystalliserer fra benzen/petroleter og omkrystalliseres 1 gang fra eter. Smeltepunkt: 97 - 98°C. To a suspension of 10.0 g of 9510-dihydro-^-H^benzo-/^:,<57cyclohepta/1,2-b/thiophene-1!--one and 30.0 g of anhydrous aluminum chloride in 200 ml of anhydrous carbon disulphide is added dropwise to a solution of 6.3 ml of succinic acid monomethyl ester chloride in 100 ml of anhydrous carbon disulphide at 0°C, the reaction mixture is further stirred for 6 hours at room temperature, 23.3 g of stannous tetrachloride is added dropwise at 20 to 25°C and further stirred for 15 hours at room temperature . The reaction mixture is then heated for 2 hours at 50°C, cooled, poured into 500 ml of 5 N hydrochloric acid and extracted with chloroform. The organic phases are washed with 5 N hydrochloric acid and with water, dried over magnesium sulfate and evaporated. The evaporation residue is dissolved in 300 ml of methylene chloride, filtered through silica gel and evaporated to dryness. The compound mentioned in the title crystallizes from benzene/petroleum ether and is recrystallized once from ether. Melting point: 97 - 98°C.
Eksempel16: ^i-il+iDkso^tø-benzo^j^cykloh^ Example 16: ^i-yl+iDkso^thoe-benzo^j^cycloh^
i+^oksosmorsyreme tålest eri+^oxosmuric acids are tolerated
I henhold til eksempel 1 fremstilles fra 10,0 g ^H-benzo-/^, 57-cyklohepta/l ^-b/tiofen-^-on, 30,0 g vannfritt aluminiumklorid og 23?3g tinntetraklorid og 6,3 ml ravsyremonometylesterklorid i 300 ml vannfritt karbondisulfid den i overskriften nevnte forbindelse og omkrystalliseres fra eter. Smeltepunkt: iMf - 1^-5°C. According to example 1, 10.0 g of ^H-benzo-/^, 57-cyclohepta/l ^-b/thiophene-^-one, 30.0 g of anhydrous aluminum chloride and 23.3 g of stannous tetrachloride and 6.3 ml are prepared succinic acid monomethyl ester chloride in 300 ml of anhydrous carbon disulphide the compound mentioned in the title and recrystallized from ether. Melting point: iMf - 1^-5°C.
Analogt med eksempel 15 eller 16 kan også de foigende ^-H-benzo-/I+,57cyklohepta/i ,2-b/tiof en-2-yl) -oksokarboksylsyreesterderivater erholdes ved omsetning av tilsvarende VH-benzo/^,57cyklohepta-pi ,2-b/tiofenderivater med tilsvarende dikarboksylsyremonoalkyl-esterhalogenider: Analogous to example 15 or 16, the following 3-H-benzo-[1+,57cyclohepta(1,2-b/thiophen-2-yl)-oxocarboxylic acid ester derivatives can also be obtained by reacting the corresponding VH-benzo[1+,57cyclohepta-pi ,2-b/thiophene derivatives with corresponding dicarboxylic acid monoalkyl ester halides:
Eksempel 26: 5-(^-okso^l+H-benzo^j^<c>y<kloh>^ Example 26: 5-(^-oxo^l+H-benzo^j^<c>y<kloh>^
2izl2i?z2^§°Y§i§ri§5-§zr®2izl2i?z2^§°Y§i§ri§5-§zr®
En blanding av 10,0 g tø-benzo/^, 57cyklohepta/"1 ,2-b/tiofen-^-on, 6,3 ml ravsyremonometylesterklorid og 80 g polyfosforsyré omrores forst i 1 time ved 80°C og deretter i 3 timer ved 120 - 130°C, avkjoles til 90°C, tilsettes 100 ml vann og vidererores ved den samme temperatur i ytterligere 1 time. Etter avkjoling til romtemperatur uthelles reaksjonsblandingen på k- 00 ml -isblandet vann, ekstraheres med metylenklorid, de organiske losninger vaskes med vann, torres over natriumsulfat og inndampes. Den i overskriften nevnte forbindelse krystalliseres fra inndampningsresten fra aceton og omkrystalliseres 1 gang. Smeltepunkt: 1^9 - 151°C. A mixture of 10.0 g of teu-benzo/^, 57cyclohepta/"1,2-b/thiophene-^-one, 6.3 ml of succinic acid monomethyl ester chloride and 80 g of polyphosphoric acid is first stirred for 1 hour at 80°C and then for 3 hours at 120 - 130°C, cooled to 90°C, 100 ml of water is added and further stirred at the same temperature for a further 1 hour. After cooling to room temperature, the reaction mixture is poured onto k- 00 ml of ice-mixed water, extracted with methylene chloride, the organic solutions are washed with water, dried over sodium sulfate and evaporated. The compound mentioned in the title is crystallized from the evaporation residue from acetone and recrystallized once. Melting point: 1^9 - 151°C.
Eksempel 27: !+: (9j10-dihydro=^=okso-^H-benz Example 27: !+: (9j10-dihydro=^=oxo-^H-benz
^"lj2;b r7tiofen- 12-yl)-l+-oksosmorsyre^"lj2;b r7thiophen-12-yl)-1+-oxosuccinic acid
En losning av 3,0 g h- (9 ? 10-dihydro-lf-okso-ifH-benzo/tf ? 5/cyklohepta/1,2-b/tiofen-2-yl)-^—oksosmorsyremetylester og 1,5 g kalium-hydroksyd i 60 ml dioksan og 30 ml vann omrores i 3 timer ved romtemperatur, fortynnes med 200 ml vann og innstilles ved 10 15°C til pH 1 med konsentrert saltsyre. Den utfelte i overskriften nevnte forbindelse ekstraheres med metylenklorid, den organiske losning vaskes med vann, torres over magnesiumsulfat, inndampes og den i overskriften nevnte forbindelse omkrystalliseres fra dimetylformamid/aceton. Smeltepunkt: 167 - 168°C. A solution of 3.0 g of h-(9 ? 10-dihydro-lf-oxo-ifH-benzo[tf ? 5/cyclohepta/1,2-b/thiophen-2-yl)-^-oxosuccinic acid methyl ester and 1.5 g of potassium hydroxide in 60 ml of dioxane and 30 ml of water is stirred for 3 hours at room temperature, diluted with 200 ml of water and adjusted at 10-15°C to pH 1 with concentrated hydrochloric acid. The precipitated compound mentioned in the title is extracted with methylene chloride, the organic solution is washed with water, dried over magnesium sulfate, evaporated and the compound mentioned in the title is recrystallized from dimethylformamide/acetone. Melting point: 167 - 168°C.
Analogt med eksempel 27 kan også de i eksempel 1 - 1<*>+ beskrevne tø-benzo/Ji-, 5/cyklohepta/l ,2-b/tiofen-2-yl)-oksokarboksylsyre-derivater fremstilles ved hydrolyse av de tilsvarende analogt med eksempel 15 eller 16 fremstillbare ^-H-benzo/^,57cyklohepta/l ,2-b/- tiofen-2-yl)-oksokarboksylsyfe-laverealkylesterderivater. Analogously to example 27, the t-benzo(((1-,5/cyclohepta(1,2-b/thiophen-2-yl))-oxocarboxylic acid derivatives described in examples 1 - 1<*>+ can also be prepared by hydrolysis of the corresponding analogously to example 15 or 16, (-H-benzo[[(57cyclohepta(1,2-b]-thiophen-2-yl)-oxocarboxylsyphe-lower alkyl ester derivatives can be prepared).
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1439673A CH581130A5 (en) | 1973-10-10 | 1973-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO743556L true NO743556L (en) | 1975-05-05 |
Family
ID=4400474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO743556A NO743556L (en) | 1973-10-10 | 1974-10-01 |
Country Status (21)
| Country | Link |
|---|---|
| JP (1) | JPS5082052A (en) |
| AT (1) | AT352107B (en) |
| AU (1) | AU498690B2 (en) |
| BE (1) | BE820943A (en) |
| CA (1) | CA1038876A (en) |
| DD (1) | DD113910A5 (en) |
| DE (1) | DE2441592A1 (en) |
| DK (1) | DK135809B (en) |
| ES (2) | ES430790A1 (en) |
| FI (1) | FI286574A7 (en) |
| FR (1) | FR2247226B1 (en) |
| GB (2) | GB1489783A (en) |
| HU (1) | HU170505B (en) |
| IE (1) | IE41615B1 (en) |
| IL (1) | IL45814A (en) |
| NL (1) | NL7413107A (en) |
| NO (1) | NO743556L (en) |
| PH (1) | PH10997A (en) |
| SE (1) | SE392272B (en) |
| SU (1) | SU548210A3 (en) |
| ZA (1) | ZA746444B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2803984A1 (en) * | 1977-02-08 | 1978-08-10 | Sandoz Ag | OXAMIC ACID DERIVATIVES, THEIR PRODUCTION AND USE |
| KR20120037913A (en) * | 2009-07-28 | 2012-04-20 | 니폰 조키 세야쿠 가부시키가이샤 | Method for producing thiabenzoazulene propionic acid derivative |
-
1974
- 1974-08-30 DE DE2441592A patent/DE2441592A1/en not_active Withdrawn
- 1974-09-30 SE SE7412312A patent/SE392272B/en unknown
- 1974-10-01 NO NO743556A patent/NO743556L/no unknown
- 1974-10-01 DK DK516174AA patent/DK135809B/en unknown
- 1974-10-01 FI FI2865/74A patent/FI286574A7/fi unknown
- 1974-10-03 PH PH16387A patent/PH10997A/en unknown
- 1974-10-04 NL NL7413107A patent/NL7413107A/en not_active Application Discontinuation
- 1974-10-08 HU HUSA2699A patent/HU170505B/hu unknown
- 1974-10-08 ES ES430790A patent/ES430790A1/en not_active Expired
- 1974-10-08 IE IE2090/74A patent/IE41615B1/en unknown
- 1974-10-08 DD DD181560A patent/DD113910A5/xx unknown
- 1974-10-09 AT AT810174A patent/AT352107B/en not_active IP Right Cessation
- 1974-10-09 CA CA211,060A patent/CA1038876A/en not_active Expired
- 1974-10-09 SU SU2065450A patent/SU548210A3/en active
- 1974-10-09 ZA ZA00746444A patent/ZA746444B/en unknown
- 1974-10-09 JP JP49115668A patent/JPS5082052A/ja active Pending
- 1974-10-09 IL IL45814A patent/IL45814A/en unknown
- 1974-10-09 AU AU74141/74A patent/AU498690B2/en not_active Expired
- 1974-10-10 FR FR7434103A patent/FR2247226B1/fr not_active Expired
- 1974-10-10 BE BE149425A patent/BE820943A/en unknown
- 1974-10-10 GB GB43893/74A patent/GB1489783A/en not_active Expired
- 1974-10-10 GB GB22272/77A patent/GB1489784A/en not_active Expired
-
1976
- 1976-07-01 ES ES449429A patent/ES449429A1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AT352107B (en) | 1979-09-10 |
| ES430790A1 (en) | 1977-04-16 |
| NL7413107A (en) | 1975-04-14 |
| IE41615B1 (en) | 1980-02-13 |
| SU548210A3 (en) | 1977-02-25 |
| FI286574A7 (en) | 1975-04-11 |
| DK135809B (en) | 1977-06-27 |
| GB1489783A (en) | 1977-10-26 |
| BE820943A (en) | 1975-04-10 |
| IE41615L (en) | 1975-04-10 |
| AU498690B2 (en) | 1979-03-22 |
| IL45814A0 (en) | 1974-12-31 |
| HU170505B (en) | 1977-06-28 |
| CA1038876A (en) | 1978-09-19 |
| ZA746444B (en) | 1976-05-26 |
| ATA810174A (en) | 1979-02-15 |
| GB1489784A (en) | 1977-10-26 |
| PH10997A (en) | 1977-10-20 |
| ES449429A1 (en) | 1977-12-01 |
| DK516174A (en) | 1975-06-09 |
| DK135809C (en) | 1977-11-28 |
| FR2247226A1 (en) | 1975-05-09 |
| FR2247226B1 (en) | 1978-07-28 |
| IL45814A (en) | 1978-06-15 |
| DE2441592A1 (en) | 1975-04-17 |
| SE392272B (en) | 1977-03-21 |
| JPS5082052A (en) | 1975-07-03 |
| AU7414174A (en) | 1976-04-15 |
| DD113910A5 (en) | 1975-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU198030B (en) | Process for production of derivatives of benzotiasole and benzotiophen and medical preparatives containing these compounds as active substance | |
| US2996503A (en) | Derivatives of heterocyclic compounds | |
| NO743186L (en) | ||
| SU873887A3 (en) | Method of preparing derivatives of imidazo-/2,1-b/-thiazoline or imidazo-/2,1-b-thiazine or their acid-additive salts in form of isomer mixture or individual isomers | |
| NO834637L (en) | PROCEDURE FOR THE PREPARATION OF NEW TIENO (2,3-6) PYRROLLER DERIVATIVES | |
| US4247706A (en) | Dibenzothiepin derivatives and a process for producing the same | |
| US3491103A (en) | Certain 4h-benzo(4,5)cyclohepta-(1,2-b) thiophenes | |
| US4544655A (en) | Antiinflammatory, analgesic, and antirheumatic 4-hydroxy-2-methyl-n-(2-pyridyl)-6-trifluoromethyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide 1,1-dioxide, corresponding compositions, and 3-carboxylic acid lower alkyl ester intermediates | |
| NO743556L (en) | ||
| CS214806B2 (en) | Method of making the derivatives of the auron | |
| US4052412A (en) | Benzo cycloheptathiophene carboxylic acid derivatives | |
| PT89268B (en) | PROCESS FOR THE PREPARATION OF HETEROCYCLIC OXOFTALAZINYL ACETTIC ACIDS | |
| US4137323A (en) | Organic compounds | |
| NO743135L (en) | ||
| US3047580A (en) | 10-(omega-amino alkyl)-10-hydroxythiaxanthenes | |
| US3086972A (en) | Aza-thiaxanthene derivatives | |
| JPH0256478A (en) | 2, 3, 4, 5-tetrahydro-1-benzoxepine-3, 5-dione derivative and production thereof | |
| NO121896B (en) | ||
| DK159110B (en) | 4H-BENZO (4,5) CYCLOHEPTA (1,2-B) THIOPHENDER DERIVATIVES, PROCEDURES FOR PREPARING IT, AND PHARMACEUTICAL PREPARATIONS CONTAINING THE DERIVATIVES | |
| US3865843A (en) | 4-Oxo-4H-benzo{8 4.5{9 cyclohepta{8 1,2-b{9 thiophene derivatives | |
| US3651051A (en) | Benzo(b)benzofurano(2 3-e)oxepines | |
| CA1276158C (en) | 4h-benzo[4,5]cyclohepta[1,2-b]thiophene derivatives | |
| DE1770722A1 (en) | 1,4,9,10-Tetra-benzo [5,6] cyclohepta [1,2-d] 4-ones and processes for their preparation | |
| IE43539B1 (en) | 2-(2'-aryl-6-chromonyl) propionic acids, and an analgesic and anti-inflammatory derivatives thereof | |
| NO851385L (en) | SUBSTITUTED BENZODIOX OLD DERIVATIVES, PROCEDURES FOR PREPARING THEREOF AND SIMILAR PHARMACEUTICAL PREPARATIONS |